Technegas at Last! Implementing Technegas into Clinical Practice in the United States: Considerations, Challenges,...

Area of Science:

• Nuclear Medicine
• Pulmonary Imaging
• Radiopharmacology

Background:

• Technegas (99mTc-labeled aerosolized carbon nanoparticles) has been utilized globally since 1986 for pulmonary ventilation imaging.
• Its gas-like behavior allows deep, uniform lung deposition, minimizing airway clumping, which is beneficial for COPD patients.

Purpose of the Study:

• To introduce Technegas, recently FDA-approved in the US, for diagnosing pulmonary embolism and other ventilation/airway evaluations.
• To outline essential considerations for implementing Technegas in US nuclear medicine departments.

Main Methods:

• The Technegas Plus system produces the radioaerosol onsite using [99mTc]sodium pertechnetate heated in a carbon crucible.
• Administration is rapid (1-3 breaths), supporting SPECT and SPECT/CT imaging for enhanced sensitivity and specificity.

Main Results:

• Technegas facilitates deep and uniform lung deposition, advantageous for patients with respiratory limitations.
• SPECT and SPECT/CT imaging with Technegas demonstrate superior sensitivity and specificity compared to planar methods.

Conclusions:

• The availability of Technegas in the US enables adoption of advanced ventilation imaging, aligning with international standards for pulmonary embolism diagnosis.
• Successful implementation requires attention to infrastructure, staff training, protocol development, and imaging optimization, enhancing diagnostic accuracy and workflow efficiency.